Douglass Winthrop Advisors LLC Raises Position in Pfizer Inc. (NYSE:PFE)

Douglass Winthrop Advisors LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 78.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 85,776 shares of the biopharmaceutical company’s stock after purchasing an additional 37,653 shares during the quarter. Douglass Winthrop Advisors LLC’s holdings in Pfizer were worth $2,276,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the stock. Retirement Wealth Solutions LLC purchased a new position in Pfizer during the fourth quarter worth $26,000. Rialto Wealth Management LLC bought a new stake in shares of Pfizer in the 4th quarter worth about $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer during the 4th quarter worth about $28,000. Noble Wealth Management PBC bought a new position in Pfizer during the 4th quarter valued at about $31,000. Finally, Curio Wealth LLC purchased a new stake in Pfizer in the 4th quarter worth about $32,000. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on PFE shares. Truist Financial cut their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Bank of America reaffirmed a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, UBS Group decreased their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Down 0.2 %

Pfizer stock opened at $26.17 on Friday. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The business has a fifty day moving average of $26.18 and a two-hundred day moving average of $27.07. The firm has a market cap of $148.29 billion, a P/E ratio of 18.56, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.10 earnings per share. On average, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.